Effects of Anticoagulants on Experimental Models of Established Chronic Liver Diseases: A Systematic Review and Meta-Analysis

Table 4

Subgroup analyses for portal pressure.

Group/subgroup	Weight (%)	Effect size		Heterogeneity for each subgroup
		MD	95% CI	(%)
All experiments	100	−1.39	(−2.33, −0.44)	45	0.07
Animal model
Liver cirrhosis	100	−1.39	(−2.33, −0.44)	45	—
Other	0	—	—	—	—
Animal species
Male	94.6	−1.25	(−2.27, −0.23)	56	0.03
Unclear	5.4	−3.28	(−7.11, 0.56)	0	0.66
Treatment duration (weeks)
≤8	100	−1.39	(−2.33, −0.44)	45	—
>8	0	—	—	—	—
Treatment timing
Simultaneous injection at model induction	21.8	0.67	(−4.92, 6.26)	90	0.001
Injection after model induction	78.2	−1.75	(−2.46, −1.03)	0	0.81
Anticoagulation type
Low molecular weight heparin (enoxaparin)	94.6	−1.25	(−2.27, −0.23)	56	0.03
Novel oral anticoagulants (rivaroxaban)	5.4	−3.28	(−7.11, 0.56)	0	0.66

CI, confidence interval; MD, mean difference.